● In Stock
CJC / IPA Blend
≥99% Purity | HPLC Verified
$100.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
Synergistic GHRH analog and ghrelin receptor agonist blend studied for amplified growth hormone release. Research use only.
Research Use OnlyNot for human or veterinary use. For in vitro laboratory research only.
| Strength | 10mg |
| molecular_formula | BLEND |
| Molecular Weight | N/A (Blend) |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
2 Pathways
Dual-Receptor Action
GHRH-R + GHSR-1a simultaneous activation
0%
Cortisol Elevation
Ipamorelin selectivity preserved in blend
0%
Prolactin Elevation
No prolactin co-secretion vs GHRP-6
99%+
Purity Verified
HPLC tested, COA included
How the CJC / Ipamorelin Blend Works
Two complementary pituitary receptor pathways activated simultaneously for synergistic GH pulse enhancement
GHRH-R Pathway
CJC-1295: GHRH Receptor Activation
CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, stimulating cAMP production and GH synthesis. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, enabling a sustained window of GHRH-R activation per dose.
- GHRH-R agonism — cAMP-mediated GH synthesis
- ~30-minute half-life for time-matched dosing
- Cortisol, thyroid, prolactin unaffected
GHSR-1a Pathway
Ipamorelin: Ghrelin Receptor Activation
Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.
- GHSR-1a agonism — PLC/IP3 intracellular pathway
- No cortisol, ACTH, or prolactin co-secretion
- ~2-hour half-life — pulsatile GH release
Synergy
Dual-Pathway Synergistic GH Amplification
When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude exceeds what either compound produces alone. Preclinical data show this additive-to-synergistic interaction: each pathway potentiates the other's pituitary response, producing larger GH pulses without proportionally increasing side effects.
- Additive GH pulse amplitude vs either alone
- Somatostatin suppression potentiated by GHSR agonism
- Physiologic pulsatile pattern preserved
What Research Has Shown
Findings from component-level studies — Raun et al. 1998 (ipamorelin); Teichman et al. 2006 (CJC-1295)
⚠️ RESEARCH NOTE
All data is derived from individual component studies (Raun et al. 1998 for ipamorelin; Teichman et al. 2006 for CJC-1295 DAC form). No published clinical trials exist specifically for the CJC-1295/Ipamorelin combination. Data should not be extrapolated to human therapeutic use.
Research Applications
Combination GH secretagogue research — dual GHRH-R + GHSR-1a pathway studies
GH Axis Research
Dual-Pathway GH Stimulation
Simultaneous GHRH-R and GHSR-1a activation produces additive GH pulse amplification — a model for studying maximal pituitary GH secretory capacity while maintaining physiologic pulse architecture.
Pulsatile GH Dynamics
Physiologic Secretion Patterns
The short half-lives of both components (~30 min for CJC-1295; ~2 hr for ipamorelin) preserve pulsatile GH release — enabling research into GH pulse physiology without continuous baseline elevation.
Endocrinology
Selectivity vs GHRP-6 Blends
CJC-1295/Ipamorelin is studied as a high-selectivity alternative to CJC-1295/GHRP-6 combinations — preserving GH stimulation amplitude while eliminating cortisol and prolactin co-secretion associated with GHRP-6.
Receptor Pharmacology
Complementary Signaling Pathways
GHRH-R signals via cAMP/PKA while GHSR-1a signals via PLC/IP3 — distinct second messenger cascades that do not compete. This orthogonal mechanism makes the combination a research model for studying receptor cross-talk in neuroendocrine signaling.
Safety Profile from Research
Combined safety data from individual component studies
✓Ipamorelin component: no cortisol, ACTH, or prolactin elevation demonstrated across dose-escalation studies — a critical safety advantage over GHRP-6-based combinations (Raun et al. 1998).
✓CJC-1295 component: selective GHRH-R agonism — cortisol, thyroid hormones, and prolactin unaffected across all doses in clinical trial data (Teichman et al. JCEM 2006).
✓No receptor desensitization observed with repeated administration of either component in preclinical study protocols.
✓Short half-lives of both components create a self-limiting, pulsatile response — GH elevation does not persist between doses as with long-acting formulations.
⚠️ This blend is not FDA-approved. No human clinical trials exist for the combination. For in vitro research use only — not for human therapeutic use.
Compound Information
Technical specifications for CJC-1295 / Ipamorelin Blend
| Blend Components | CJC-1295 (Modified GRF 1-29) + Ipamorelin |
| CJC-1295 Type | GHRH analog — GHRH-R agonist (no DAC modification) |
| Ipamorelin Type | Pentapeptide GH secretagogue — GHSR-1a agonist |
| CJC-1295 MW | 3,367.9 g/mol |
| Ipamorelin MW | 711.9 g/mol |
| CJC Half-Life | ~20–30 minutes |
| Ipamorelin Half-Life | ~2 hours |
| Form | Lyophilized powder (co-lyophilized blend) |
| Purity | ≥99% each component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for up to 24 months |
| Storage (reconstituted) | 2–8°C, use within 30 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
Frequently Asked Questions
Common questions about CJC-1295 / Ipamorelin Blend research
The CJC-1295/Ipamorelin blend combines two peptides that stimulate pituitary GH release through distinct, complementary receptor systems. CJC-1295 (Modified GRF 1-29) activates GHRH receptors (GHRH-R) via the cAMP/PKA intracellular pathway. Ipamorelin activates GHSR-1a (ghrelin receptors) via the PLC/IP3 pathway. Because these are separate receptor populations using different second messenger systems, simultaneous activation produces additive-to-synergistic GH pulse amplification without receptor competition or off-target hormone effects.
Both ipamorelin and GHRP-6 are GHSR-1a agonists, but ipamorelin is significantly more selective. GHRP-6 co-elevates cortisol, ACTH, and prolactin — stress and pituitary hormones that confound research readouts. Ipamorelin produces comparable GH stimulation without these side effects (Raun et al. 1998). For research protocols requiring isolated study of GH/IGF-1 axis effects, the CJC-1295/Ipamorelin combination provides cleaner data by eliminating cortisol and prolactin as variables.
Pulsatile GH secretion means GH is released in discrete bursts rather than a steady continuous stream. Endogenously, this occurs 6–12 times per day, with the largest pulses during slow-wave sleep. The pulsatile pattern is important because GH receptor sensitivity, downstream IGF-1 production, and metabolic effects all depend on the pulse amplitude and inter-pulse interval. CJC-1295/Ipamorelin preserves this pulsatile architecture (due to short half-lives) — making it a tool for studying GH pulse physiology rather than pharmacological continuous GH replacement.
Direct combination studies have not been published in the peer-reviewed literature. The scientific rationale for the combination is derived from: (1) Ipamorelin pharmacology demonstrating GHSR-1a selective GH stimulation (Raun et al. 1998); (2) CJC-1295 clinical trial data showing GHRH-R-mediated GH/IGF-1 elevation (Teichman et al. JCEM 2006); and (3) preclinical studies demonstrating additive GH responses when GHRH and GH secretagogues are co-administered, reviewed by Muller et al. (1999).
No. Neither CJC-1295 without DAC nor ipamorelin is FDA-approved for any indication, and the combination has no regulatory approval. Both are research compounds classified as not intended for human therapeutic use. This blend is sold exclusively for in vitro research purposes.
The lyophilized powder blend should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Both components maintain stability in lyophilized form; CJC-1295 is relatively more sensitive to DPP-IV degradation in solution due to the absence of albumin binding.
Sources & References
PubMed
Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
2006
PubMed
Ghrelin and the GH secretagogue receptor: from discovery to therapeutic use
2001
⚠️ For research use only. Not for human or veterinary therapeutic use. These statements have not been evaluated by the Food and Drug Administration.
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
CJC / IPA Blend
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
